Pharmaceuticals Japan

Japan CAR-T Cell Therapy Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Japan CAR-T Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $337.5 Mn Placeholder estimate
Estimate 2025 $420.2 Mn 6.5% of the global market
Projected 2034 $3.02 Bn 618.7% Adds $2.60 Bn over 9 forecast years
CAGR 2025–2034 24.5% Faster than 92% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Japan is 6.51% of the global market.
  • In APAC, the largest is China at $539.6 Mn.
  • Fastest growing: India at 27.1% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.60 Bn total, 2026–2034

Year-by-year market size, 2024–2034
CAR-T Cell Therapy Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $337.5 Mn — —
2025 (base) $420.2 Mn +$82.7 Mn —
2026 (forecast) $523.2 Mn +$103.0 Mn +24.5%
2027 (forecast) $651.3 Mn +$128.2 Mn +55%
2028 (forecast) $810.9 Mn +$159.6 Mn +93%
2029 (forecast) $1.01 Bn +$198.7 Mn +140.3%
2030 (forecast) $1.26 Bn +$247.3 Mn +199.1%
2031 (forecast) $1.56 Bn +$308.0 Mn +272.4%
2032 (forecast) $1.95 Bn +$383.4 Mn +363.6%
2033 (forecast) $2.43 Bn +$477.3 Mn +477.2%
2034 (forecast) $3.02 Bn +$594.3 Mn +618.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $6.46 Bn
  2. North America $3.01 Bn
  3. US $2.51 Bn
  4. APAC $1.19 Bn
  5. Europe $1.10 Bn
  6. China $539.6 Mn
  7. Canada $445.6 Mn
  8. Japan (this report) $420.2 Mn
  9. Latin America $313.2 Mn
  10. Germany $244.3 Mn
  11. Middle East $227.1 Mn
  12. France $188.8 Mn
  13. UK $181.1 Mn
  14. Brazil $176.7 Mn
  15. Italy $161.3 Mn
  16. India $138.3 Mn
  17. Saudi Arabia $127.4 Mn
  18. Ecuador $117.0 Mn
  19. Spain $110.6 Mn
  20. Mexico $109.0 Mn
  21. Africa $98.4 Mn
  22. Russia $76.4 Mn
  23. Australia $74.9 Mn
  24. New Zealand $68.7 Mn
  25. South Africa $37.6 Mn
  26. UAE $27.9 Mn
  27. Egypt $17.1 Mn
  28. Philippines $14.1 Mn
  29. Hong Kong $10.9 Mn
  30. Malaysia $9.7 Mn
  31. Singapore $7.0 Mn
  32. Thailand $6.9 Mn
  33. Kenya $4.5 Mn

Report snapshot

Japan CAR-T Cell Therapy Market Analysis at a glance
Market size, 2025$420.2 Mn placeholder estimate
Forecast, 2034$3.02 Bn placeholder estimate
Growth (CAGR), 2025–203424.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTarget, indication and end user (see all)
Key playersGilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson, Legend Biotech and 1 more (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
Active clinical trials26 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan CAR-T Cell Therapy Market Analysis Executive Summary

CAR-T cell therapy changes a patient's own immune T cells so they can find and kill cancer cells, mainly in blood cancers.

Key segments of the CAR-T Cell Therapy market include target (CD19, BCMA and Others) and indication (Lymphoma, Leukemia and Multiple Myeloma).

Bar chart: Japan CAR-T Cell Therapy market size, 2024–2034, placeholder estimates. $337.5 Mn in 2024, $420.2 Mn in 2025 and $3.02 Bn in 2034, 24.5% CAGR.
Japan CAR-T Cell Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan CAR-T Cell Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the CAR-T Cell Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the CAR-T Cell Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the CAR-T Cell Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for CAR-T Cell Therapy Market in Japan

The CAR-T Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for CAR-T Cell Therapy Market in Japan

CAR-T Cell Therapy in Japan: rules, payment and research

Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2] ClinicalTrials.gov lists 26 studies on CAR-T Cell Therapy that are recruiting, active or about to start in Japan.⁠[3]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for CAR-T Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in CAR-T Cell Therapy right now, from free public sources.

Clinical trials

26 active trials in Japan

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Chongqing Precision Biotech Co., Ltd 25 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Bristol-Myers Squibb 13 active trials on ClinicalTrials.gov (opens in a new tab)
  3. AstraZeneca 12 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Novartis AG 11 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Hebei Senlang Biotechnology Inc., Ltd. 9 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 7,618 papers since 2021 (worldwide)

  1. Ligand/receptor-based chimeric antigen receptors: a promising alternative to conventional scFv designs in cancer immunotherapy. Transplantation and cellular therapy, 2026
  2. Acute Neurotoxicity Syndromes from Immunotherapy: Emergency and ICU Management. Seminars in neurology, 2026
  3. LILRB1 as a novel therapeutic target for CAR-T therapy in diffuse large B cell lymphoma. Molecular therapy : the journal of the American Society of Gene Therapy, 2026
  4. Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones. PloS one, 2026
  5. Cell-based Therapies in Acute Lymphoblastic Leukemia Treatment: Current Advancements and Limitations. Clinical and experimental medicine, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

CAR-T Cell Therapy in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the CAR-T Cell Therapy market in Japan?
Placeholder estimate: about $420.2 Mn in 2025, rising to about $3.02 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the CAR-T Cell Therapy market in Japan growing?
Placeholder estimate: about 24.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the CAR-T Cell Therapy market report cover?
The report splits the market by target (CD19, BCMA, Others), indication (Lymphoma, Leukemia, Multiple Myeloma, Autoimmune Diseases) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the CAR-T Cell Therapy market?
Key players include Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson, Legend Biotech and Autolus Therapeutics.
What is driving the CAR-T Cell Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the CAR-T Cell Therapy market.
Who regulates CAR-T Cell Therapy in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on CAR-T Cell Therapy are running in Japan?
26 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
How much research is published on CAR-T Cell Therapy?
PubMed lists 7,618 papers on CAR-T Cell Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about CAR-T Cell Therapy in Japan? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Bioinformatics: Making Sense of Health DataSequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics… Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Japan

See all
Same topic, other categories

Related on cell and gene therapy and oncology

See the topic